Reteplase, Recombinant Human tissue plasminogen activator

Specification

• Cat#: THP-0135
• Product Name: Reteplase, Recombinant Human tissue plasminogen activator
• Cas No: 133652-38-7
• Description: Recombinant Human tissue plasminogen activator(tPA), purified, glycosylated, 355 a.a. expressed in CHO cells. The product is genetically engineered to retain and delete certain portions of human tPA. The product is a deletion mutein of human tPA formed by deleting various amino acids present in endogenous human tPA. The product contains 355 of the 527 amino acids of native human tPA (amino acids 1-3 and 176-527), and retains the activity-related kringle-2 and serine protease domains of human tPA. Three domains are deleted from the product - kringle-1, finger, and epidermal growth factor (EGF).
• Sequences: SYQGNSDCYFGNGSAYRGTHSLTESGASCLPWNSMILIGKVYTAQNPSAQALGLGKHNYCRNPDGDAKPWCHVLKNRRLTWEYCDVPSCSTCGLRQYSQPQFRIKGGLFADIASHPWQAAIFAKHRRSPGERFLCGGILISSCWILSAAHCFQERFPPHHLTVILGRTYRVVPGEEEQKFEVEKYIVHKEFDDDTYDNDIALLQLKSDSSRCAQESSVVRTVCLPPADLQLPDWTECELSGYGKHEALSPFYSERLKEAHVRLYPSSRCTSQHLLNRTVTDNMLCAGDTRSGGPQANLHDACQGDSGGPLVCLNDGRMTLVGIISWGLGCGQKDVPGVYTKVTNYLDWIRDNMRP
• Species: Human
• Molecular Weight: 39589.6 Da
• Source: CHO
• Purity: >99% by SDS-Page and HPLC analysis
• Formula: C1736H2671N499O522S22
• Endotoxin: <0.001 EU per 1 μg of the protein by the LAL method
• Biological Activity: 10.4 unit / vial
• Application: For lysis of acute pulmonary emboli, intracoronary emboli and management of myocardial infarction.

Pharmaceutical Information

• Pharmaceutical Application: Reteplase
• Targets: Target 1. Plasminogen; Target 2. Fibrinogen alpha chain; Target 3. Urokinase plasminogen activator surface receptor; Target 4. Plasminogen activator inhibitor 1